Psychedelic State of the Union - Lightning in a Bottle 2018

Psychedelic research and its integration into contemporary society are evolving through a shift from the historical war-on-drugs paradigm toward evidence-based clinical application. Research is currently focused on leveraging substances such as MDMA to treat complex conditions like PTSD, aiming to foster healing and community resilience rather than simply suppressing symptoms. This transition requires a nuanced understanding of trauma, acknowledging the systemic and individual impacts, while creating safe settings for therapeutic exploration. Clinical efforts led by MAPS seek to establish standardized, FDA-approved protocols for psychedelic-assisted psychotherapy. By transitioning these substances from the underground into legitimate medical frameworks, the broader societal conversation is being reshaped to balance clinical efficacy with necessary safeguards for public access and education.